Replies to post #173215 on Biotech Values

[DewDiligence]

GILD/ABBV/ENTA—This sounds like posturing by the PBMs and third-party payers to induce GILD to set the price of the not-yet-approved Sovaldi + Ledipasvir combination at a small (or zero) premium to Sovaldi itself.

[DewDiligence]

#msg-98109561 contains the latest update on the story you posted in January.